<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="species">human</item><item key="factors"><item><item key="GSM966545"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with shETV1 were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966545"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with shETV1 were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966545"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with shETV1 were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966542"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966542"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966542"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966539"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with shETV1 were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966539"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with shETV1 were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966539"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with shETV1 were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966536"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966536"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966536"><item key="CELL LINE">LNCAP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966533"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siERG were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966533"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siERG were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966533"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siERG were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966530"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966530"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966530"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of 10nM DHT</item></item></item><item><item key="GSM966527"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siERG were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966527"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siERG were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966527"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siERG were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966524"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966524"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item><item><item key="GSM966524"><item key="CELL LINE">VCaP</item><item key="TREATMENT">transfected with siControl were grown in androgen deprived serum for 2 days and then in the presence of EtOH</item></item></item></item><item key="id">2526</item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">4</item><item key="summary_wrapped">Chromosomal rearrangements involving ETS factors, ERG and ETV1, occur frequently in prostate cancer. We here examine human prostate...</item><item key="geo_gse_id">E-GEOD-39354</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">2</item><item key="sample_count">24</item><item key="tags"><item>cancer</item><item>hormone</item><item>prostate</item><item>prostate cancer</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_id_plat">E-GEOD-39354_A-AFFY-44</item><item key="slug">expression-profiling-of-human-prostate-vcap-and-ln</item><item key="geo_gds_id"/><item key="name">Expression profiling of human prostate VCaP and LNCaP cancer cells after silencing ERG or ETV1, respectively</item><item key="created">Jul.12, 2014</item><item key="summary">Chromosomal rearrangements involving ETS factors, ERG and ETV1, occur frequently in prostate cancer. We here examine human prostate cancer cells control VCaP and LNCaP cells with ERG- or ETV1-silenced VCaP or LNCaP cells, respectively, in hormone deprived and stimulated conditions. VCAP and LNCaP cells, 24 hr after ERG or ETV1 RNA interference, respectively, were grown in hormone-depleted conditions for 2 days, and then in the presence of EtOH (vehicle) or 10nM DHT for 16hr. Total RNA was extracted from three biological replicates. This was used to hybridize to Affymetrix expression arrays using the HG-U133 Plus 2.0 platform.</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39354</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39354/samples/</item></data></biogps>
